Home › Research › Drug development
The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation
Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM.. Brain research. Molecular brain research, 1998-06-01
Topic: Disease mechanisms in lab and animal studies
Plain-language summary
The beta-amyloid peptide (Abeta) is deposited in neuritic plaques which are characteristic features of Alzheimer's disease (AD). Prominent neurodegeneration and glial activation occurs around these plaques leading to the hypothesis that Abeta may play a causative role in the neuronal loss and the inflammatory response associated with AD. Here we show that Abeta-induced toxicity of cultured fetal rat cortical neurons is associated with internucleosomal DNA fragmentation beginning just 6 h after neurons are exposed to Abeta. Additionally, constitutive NF-kappaB activity readily measured in fetal rat cortical neurons decreases in a concentration- and time-dependent fashion following exposure to Abeta, but there is no corresponding decrease in NF-kappaB mRNA or protein (p65). An upregulation of both IkappaB alpha protein and mRNA which occurs in cortical neurons exposed to Abeta may be responsible for retaining NF-kappaB in the cytoplasm accounting for the observed decrease in activated NF-kappaB. The latter is supported by the observation that pretreatment of cortical cultures with an antisense oligonucleotide to IkappaBalpha mRNA is neuroprotective. In contrast to cortical neurons, exposure of rat primary astroglial cultures to Abeta results in a concentration- and time-dependent activation of NF-kappaB with subsequent upregulation of IL-1beta and IL-6. Our data suggest that Abeta-induced neurotoxicity as well as astrocyte activation may be medicated by the NF-kappaB/Rel family of proteins, and thus alterations in NF-kappaB-directed gene expression may contribute to both the neurodegeneration and inflammatory response which occur in AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bales, K. R., Du, Y., Dodel, R. C., Yan, G. M., Hamilton-Byrd, E., & Paul, S. M. (1998). The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain research. Molecular brain research. https://doi.org/10.1016/s0169-328x(98)00066-7
Vancouver
Bales KR, Du Y, Dodel RC, Yan GM, Hamilton-Byrd E, Paul SM. The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Brain research. Molecular brain research. 1998. doi:10.1016/s0169-328x(98)00066-7. PMID: 9630519.
BibTeX
@article{bales1998-9630519,
author = {Bales, K. R. and Du, Y. and Dodel, R. C. and Yan, G. M. and Hamilton-Byrd, E. and Paul, S. M.},
title = {{The NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation}},
journal = {Brain research. Molecular brain research},
year = {1998},
doi = {10.1016/s0169-328x(98)00066-7},
pmid = {9630519},
url = {https://doi.org/10.1016/s0169-328x(98)00066-7}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Prominent neurodegeneration and glial activation occurs around these plaques leading to the hypothesis that Abeta may play a causative role in the neuronal loss and the inflammatory response associated with AD.
- Here we show that Abeta-induced toxicity of cultured fetal rat cortical neurons is associated with internucleosomal DNA fragmentation beginning just 6 h after neurons are exposed to Abeta.
- In contrast to cortical neurons, exposure of rat primary astroglial cultures to Abeta results in a concentration- and time-dependent activation of NF-kappaB with subsequent upregulation of IL-1beta and IL-6.
- Our data suggest that Abeta-induced neurotoxicity as well as astrocyte activation may be medicated by the NF-kappaB/Rel family of proteins, and thus alterations in NF-kappaB-directed gene expression may contribute to both the neurodegeneration and inflammatory response which occur in AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 21 of the 58 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain research. Molecular brain research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1998 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 9630519) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 21 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 21 of the 58 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Drug development from nearby years
Also tagged “presenilin”
343 studies in the library carry the topic tag “presenilin”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 343 tagged studies.